Armour Thyroid
(Thyroid hormone)Phase 1Small molecule
Merck & Co.This medication replaces the thyroid hormone that your body isn't making enough of, helping to relieve symptoms of an underactive thyroid such as fatigue, depression, weight gain, and cold sensitivity. It's also used to treat an enlarged thyroid gland.[1] Armour Thyroid is currently being investigated across 1 indication[3], with its most advanced program in Phase 1.[1]
Armour Thyroid is one of 24 small molecule programs targeting Type 2 Diabetes. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1NOVOLIN R
Novo NordiskPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Lovaza
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
Armour Thyroid
Merck & Co.Phase 1
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Thyroid hormone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company